2017
DOI: 10.1002/cpt.602
|View full text |Cite|
|
Sign up to set email alerts
|

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Abstract: Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
212
0
4

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 253 publications
(217 citation statements)
references
References 81 publications
1
212
0
4
Order By: Relevance
“…27 When it comes to the best strategy for PGx testing, the lack of consensus could be due to the fact that the concept is relatively new and so far only limited to the USA and some European countries. 29,30 Emerging data have been supportive of the pre-emptive PGx testing approach. By using EMRs and multi-gene testing platforms, pre-emptive genotyping is believed to provide an efficient mechanism to improve therapeutic decisions and outcomes based on PGx testing.…”
Section: Attitudes Towards Implementation Of Pgx Testingmentioning
confidence: 99%
“…27 When it comes to the best strategy for PGx testing, the lack of consensus could be due to the fact that the concept is relatively new and so far only limited to the USA and some European countries. 29,30 Emerging data have been supportive of the pre-emptive PGx testing approach. By using EMRs and multi-gene testing platforms, pre-emptive genotyping is believed to provide an efficient mechanism to improve therapeutic decisions and outcomes based on PGx testing.…”
Section: Attitudes Towards Implementation Of Pgx Testingmentioning
confidence: 99%
“…So far, results of prospective randomized trials have been presented only for a very limited number of drugs [133]. In Europe, a large prospective trial called PRE-PARE (PREemptive pharmacogenomic testing for Preventing Adverse drug REactions) has been initiated by the EU-financed Ubiquitous Pharmacogenomics project (http://upgx.eu/) that ai ms to im plem ent and ev aluat e the i mpac t of pharmacogenomic testing on therapeutic outcomes in seven European clinical centers [134]. In total, 8100 patients will be enrolled and 40 clinically relevant PGx markers across 13 important pharmacogenes will be analyzed.…”
Section: Clinical Implementation Of Pharmacogenomicsmentioning
confidence: 99%
“…Decision making with regard to the implementation of an alert depends on evidence-based guidelines that come from sources such as CPIC, the Clinical Pharmacogenetics Implementation Consortium (https://cpicpgx.org/guidelines/), a collaboration between the PGRN and the PharmGKB database or a similar European consortium, the Dutch Pharmacogenetics Working Group. It should be emphasized that, even though this review has generally focused on North American pharmacogenomic discovery and implementation efforts, these efforts are truly international in scope—as illustrated, for example, by the European “Ubiquitous Pharmacogenomics Consortium.” 28 Current drug-gene pair alerts are primarily “reactive”, ie, they require that the physician—on the basis of his or her goals for the patient—order the genetic test in response to the alert. Although an important first step, reactive alerts represent only one step toward the eventual goal, which would involve having pharmacogenomic data for a specific patient “preemptively” available in the EHR so there will be no delay associated with waiting for a test result so the pharmacogenomic information can be incorporated into the clinical workflow seamlessly.…”
Section: Pharmacogenomics: Clinical Implementationmentioning
confidence: 99%